The combination of cisplatin and ifosfamide on day 1 plus vinorelbine on day 1 and 8, every 3 weeks, has demostrated a high response rate and acceptable toxicities in advanced NSCLC patients. The present study was designed to analyse the feasibility and toxicity of a similar regimen in which vinorelbine was administered on a weekly basis in advanced NSCLC patients. The scheme consisted of cisplatin 80 mg/sqm, Ifosfamide 3 gr/sqm on day 1, Vinorelbine 25 mg/sqm on days 1,8,15, every 21 days. The dose of vinorelbine on day 8 and 15 was modified according to the absolute neutrophil count. Patients who experienced grade 3-4 neutropenia received G-CSF (300 micrograms total dose subcutaneously) from days 10 to 13 and from 17 to 20 of each subsequent course. Twelve patients were treated and forty-six courses were evaluable for toxicity. Grade 3-4 neutropenia was observed in 63\% of the courses; 3 episodes of febrile neutropenia were recorded. Vinorelbine on day 15 was omitted in 52\% of the courses and was given at 75\% and 50\% of the planned dose in 11\% and 4.3\% respectively; G-CSF was administered in 65.2\% of the courses. This scheme is not feasible because of the high incidence of grade 3-4 neutropenia. In spite of G-CSF, the dose of vinorelbine on day 15 was omitted or reduced in the majority of the cycles.

A pilot study with cisplatin, ifosfamide and weekly administration of vinorelbine as an outpatient combination chemotherapy for advanced non small cell lung cancer / C., Tibaldi; E., Baldini; S., Ricci; Conte, Pierfranco. - In: ANTICANCER RESEARCH. - ISSN 0250-7005. - STAMPA. - 16:(1996), pp. 3213-3215.

A pilot study with cisplatin, ifosfamide and weekly administration of vinorelbine as an outpatient combination chemotherapy for advanced non small cell lung cancer.

CONTE, Pierfranco
1996

Abstract

The combination of cisplatin and ifosfamide on day 1 plus vinorelbine on day 1 and 8, every 3 weeks, has demostrated a high response rate and acceptable toxicities in advanced NSCLC patients. The present study was designed to analyse the feasibility and toxicity of a similar regimen in which vinorelbine was administered on a weekly basis in advanced NSCLC patients. The scheme consisted of cisplatin 80 mg/sqm, Ifosfamide 3 gr/sqm on day 1, Vinorelbine 25 mg/sqm on days 1,8,15, every 21 days. The dose of vinorelbine on day 8 and 15 was modified according to the absolute neutrophil count. Patients who experienced grade 3-4 neutropenia received G-CSF (300 micrograms total dose subcutaneously) from days 10 to 13 and from 17 to 20 of each subsequent course. Twelve patients were treated and forty-six courses were evaluable for toxicity. Grade 3-4 neutropenia was observed in 63\% of the courses; 3 episodes of febrile neutropenia were recorded. Vinorelbine on day 15 was omitted in 52\% of the courses and was given at 75\% and 50\% of the planned dose in 11\% and 4.3\% respectively; G-CSF was administered in 65.2\% of the courses. This scheme is not feasible because of the high incidence of grade 3-4 neutropenia. In spite of G-CSF, the dose of vinorelbine on day 15 was omitted or reduced in the majority of the cycles.
16
3213
3215
A pilot study with cisplatin, ifosfamide and weekly administration of vinorelbine as an outpatient combination chemotherapy for advanced non small cell lung cancer / C., Tibaldi; E., Baldini; S., Ricci; Conte, Pierfranco. - In: ANTICANCER RESEARCH. - ISSN 0250-7005. - STAMPA. - 16:(1996), pp. 3213-3215.
C., Tibaldi; E., Baldini; S., Ricci; Conte, Pierfranco
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/739335
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact